tbuckley/cabot-search huggingface dataset:
FT1050 (16,16-dimethyl Prostaglandin E2)-Enhanced Umbilical Cord Blood Accelerates Hematopoietic Engraftment After Reduced Intensity Conditioning and Double Umbilical Cord Blood Transplantation
Authors: Corey S. Cutler, Daniel Shoemaker, Karen K. Ballen, David Robbins, Caroline Desponts, Grace S. Kao, Yi-Bin A. Chen, Bimalangshu R. Dey, Steven L. McAfee, Edwin P Alyea, John Koreth, Philippe Armand, Vincent T Ho, Haesook T Kim, Wolfram Goessling, Trista E. North, Thomas R. Spitzer, Robert J. Soiffer, Joseph H. Antin, Jerome Ritz, John Mendlein, Pratik S. Multani
Journal: Blood (2011)
Backtracking Of The Genetic Events Preceding Acute Leukemia Diagnosis
Authors: Olga Zimmermannova, Marketa Zaliova, Ester Mejstrikova, Eva Fronkova, Marie Jarosova, Zuzana Zemanova, Libuse Lizcova, Halima A Al-Shehhi, Anthony V. Moorman, Ajay J Vora, Claus Meyer, Rolf Marschalek, Jan Stary, Jan Trka, Ondrej Hrusak, Jan Zuna
Journal: Blood (2013)
Hepatitis E Virus Infection after Haploidentical Hematopoietic Stem Cell Transplantation:Incidence and Clinical Course
Authors: Fei-Fei Tang, Xiao-Dong Mo, Yu Wang, Chen-Hua Yan, Yu-Hong Chen, Huan Chen, Wei Han, Ying-Jun Chang, Hai-Ying Zhang, Yan-Di Xie, Hui Ma, Lai Wei, Lan-Ping Xu, Xiao-Jun Huang, Xiaohui Zhang
Journal: Blood (2018)
Use of Next Generation Sequencing Panel to Clarify Undiagnosed Cases of Hereditary Hemolytic Anemias
Authors: Elisa Fermo, Cristina Vercellati, Anna Paola Marcello, Ebru Yilmaz Keskin, Aurora Feliu Torres, Silverio Perrotta, Tekin Aksu, Anna Zaninoni, Valentina Brancaleoni, Richard van Wijk, Sultan Aydin Koker, Alberto Zanella, Agostino Cortelezzi, Wilma Barcellini, Paola Bianchi
Journal: Blood (2017)
Abstract 452: A Unique Acylcarnitine Profile is Independently Associated with Diabetic Heart Failure and Associates with Adverse Clinical Outcomes: Insights from the FIGHT Trial
Authors: Joseph B Lerman, Stephanie N Giamberardino, Steven E McNulty, William E Kraus, Christopher L Holley, Adrian F Hernandez, Svati H Shah, Robert W McGarrah
Journal: Circulation Research (2019)

Introduction: Heart failure with reduced ejection fraction (HFrEF) may be associated with unique metabolic derangements in patients with type 2 diabetes (T2DM). However, whether such derangements are associated with clinical outcomes remains unclear. Purpose: 1) To determine metabolic pathways that are dysregulated in high-risk HFrEF with and without T2DM. 2) To identify metabolomic signatures which may be differentially associated with clinical outcomes in HFrEF patients with T2DM. Methods: The FIGHT trial studied the effect of liraglutide on clinical stability in individuals with advanced HFrEF. Forty-five metabolites were quantified in 254 baseline plasma samples from the trial (T2DM: n=147, non-T2DM: n=107) using tandem flow injection mass spectrometry. Principal component analysis (PCA) was used to reduce the high number of correlated metabolites into uncorrelated factors. Linear regression was used to evaluate the association of T2DM with PCA-derived factor levels. Cox proportional hazards models, stratified by T2DM status, were used to test for time to mortality or HF hospitalization. Results: Patients with T2DM were older, had higher BMI, and were more likely to have CAD, but had similar gender composition and severity of HF, as compared with non-T2DM patients. PCA identified 13 metabolite factors grouping in biologically consistent pathways. T2DM status was associated with two factors, one composed of the short chain dicarboxyl-acylcarnitine, C6-DC, and the long-chain acylcarnitine C22 (β= -0.325, p=0.016), and one composed of aspartic acid/asparagine (β= -0.373, p=0.008), in fully adjusted models. The same C6-DC, C22 factor was associated with time to mortality or HF hospitalization beyond adjustment for sex, race, liraglutide exposure, baseline age, systolic blood pressure, creatinine, BMI, NT-pro-BNP, and liver function (T2DM: HR 1.573, p=0.007; Non-T2DM: HR 1.302, p=0.103). Conclusions: Amongst patients with high-risk HFrEF, those with T2DM had differential levels of a short chain dicarboxyl- and long-chain acylcarnitine, which were associated with adverse clinical outcomes. Such metabolites might serve as potential targets for diagnostic or therapeutic interventions in diabetic HFrEF.
Financial toxicity among veterans with cancer.
Authors: Divya Ahuja Parikh, Meera Vimala Ragavan, Sana Khateeb, Manali I. Patel
Journal: Journal of Clinical Oncology (2019)

103 Background: Financial toxicity of cancer care has not previously been studied within the Veterans Health Administration (VHA). The VHA provides health care for veterans in VA hospitals across the United States (US). It is a single-payer system and the largest integrated health system in the US and in this study we sought to assess financial toxicity experienced by veterans at a VA hospital. Methods: We asked veterans with oncology clinic visits at the VA Palo Alto to complete a survey that included an 11-item validated questionnaire called the COST tool. The COST tool calculates a score 0-44 with higher scores suggestive of higher financial toxicity. We also assessed demographic factors including gender, education, race, income, and insurance status as well as monthly out of pocket costs (OOPC) and suggested resources to reduce burden. We coded responses and calculated descriptive statistics with proportions. Results: A total of 84 veterans completed the survey and demographic factors are depicted in Table. Veterans were predominantly male (96%), high school or less educated (46%), white (61%), with annual income less than $50,000 (81%), and VA insurance (95%). The mean COST score was 21. The majority of veterans (63%) reported less than $100 of monthly OOPC and many (56%) reported transportation as a major expense and requested transportation resources. Conclusions: Financial toxicity is an unmet concern among veterans. Despite low monthly OOPC in the VHA single-payer system, financial toxicity as measured by the COST score at a VA hospital was as high as a nearby academic center. Transportation was the most significant expense and future studies should evaluate interventions to reduce the financial burden of transportation for veterans. [Table: see text]
Second primary melanoma: Risk factors, histopathologic features, and survival
Authors: H. F. Schoellhammer, H. Torisu-Itakura, Y. Huynh, M. Sim, M. B. Faries, D. L. Morton
Journal: Journal of Clinical Oncology (2009)

9073 Background: Melanoma incidence in the United States is expected to be 4.3% of all cancers in 2008. Cutaneous melanoma patients are at risk for second primary melanoma development. Our goal was to characterize the histopathologic features, risk factors, and patient survival for second primary melanoma. Methods: A review of the melanoma database established in 1971 at John Wayne Cancer Institute was conducted identifying patients with American Joint Committee on Cancer (AJCC) stage I and II cutaneous melanoma who later developed a second primary melanoma. Patients were grouped by Breslow thickness, Clark level, and histopathologic subtype (superficial spreading [SSM], nodular, acral lentiginous, lentigo maligna, and in situ). Multivariate analysis involving age, gender, Breslow thickness, Clark level, and ulceration status was performed to determine an effect on development of second primary. Kaplan-Meier survival curves were plotted for single primary and second primary melanoma patients. Results: Second primary melanoma was identified in 411 (3.7%) of 10,968 patients with AJCC stage I-II melanoma. The most common first primary subtype was SSM, and 93% of these patients had in situ or SSM as the second primary. Sixty-five percent of first primaries had a Breslow thickness of ≤1 mm, and 75% of second primaries had a thickness ≤1 mm. Forty-nine percent of first primaries had Clark level I or II, but 68% of second primaries had Clark level I or II. In multivariate analysis, only increasing age was significantly associated with the likelihood of second primary melanoma (p&lt;0.0001). With increasing follow-up time the hazard ratio of second primary melanoma was 1.31 for every decade. Overall survival for second primary melanoma patients was better than for single primary patients (p&lt;0.0001). Conclusions: Most second primary melanoma patients will have SSM or in situ, with a decreased Clark level and Breslow thickness. Contrary to expectations, patients developing second primary melanoma did not exhibit decreased overall survival. Increased follow-up time after first primary melanoma is a significant risk factor for second primary development, thus illustrating the importance of lifelong patient follow-up. No significant financial relationships to disclose.
Cost implications of growth in new cancer drugs in a comprehensive cancer center.
Authors: Sukanya Murali Venkatesan, Anamika Chaudhuri, Belen Fraile
Journal: Journal of Clinical Oncology (2019)

112 Background: Rising costs of cancer therapies calls for strategizing towards sustainable care delivery models from a hospital planning, payer as well as policy-making perspective. This topic becomes increasingly significant as there is exponential growth of novel, high-cost immunotherapy drugs making it imperative for players to adopt and practice value-based oncology. Objective: This study aims to evaluate increasing trends in use of new and transformative cancer therapies, and associated drug costs in a comprehensive cancer center in Massachusetts. Methods: Study period was fiscal year (FY) 2015-2018. Utilization was defined by the number of patients receiving infusion and number of visits made by them to the center during the FY. Cost was defined as expense to hospital. Data source was hospital billing database. ASP (Average Sales Price) of drug was obtained from CMS website and was used as an indicator for cost per unit of the drug. Results: Top 10 drugs were identified based on total cost incurred in the study period and contributed to almost a third of center’s total cost. Over the three years, number of visits for these drugs grew up to 700% and treated patients grew up to 350%. Use of chemotherapy in isolation decreased from 35% of treated patients in FY15 to 26% in FY18, whereas its use in combination with immunotherapy increased from 22% in FY15 to 28% in FY18. Average drug cost to hospital per patient for the study period ranged as high as $120,000 (excluding non-drug treatment costs). Conclusions: While clinical value of the new cancer therapies is unquestionably significant, there is a dire need for policy-makers, providers and payers alike to pay continued attention towards its high cost implications as observed in this study and, continue striving towards establishing more sustainable pricing policies through alternative payment models.
Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort
Authors: Lucie M. Turcotte, Qi Liu, Yutaka Yasui, Tara O. Henderson, Todd M. Gibson, Wendy Leisenring, Michael A. Arnold, Rebecca M. Howell, Daniel M. Green, Gregory T. Armstrong, Leslie L. Robison, Joseph P. Neglia
Journal: Journal of Clinical Oncology (2019)

Therapeutic radiation in childhood cancer has decreased over time with a concomitant increase in chemotherapy. Limited data exist on chemotherapy-associated subsequent malignant neoplasm (SMN) risk.SMNs occurring > 5 years from diagnosis, excluding nonmelanoma skin cancers, were evaluated in survivors diagnosed when they were < 21 years old, from 1970 to 1999 in the Childhood Cancer Survivor Study (median age at diagnosis, 7.0 years; median age at last follow-up, 31.8 years). Thirty-year SMN cumulative incidence and standardized incidence ratios (SIRs) were estimated by treatment: chemotherapy-only (n = 7,448), chemotherapy plus radiation (n = 10,485), radiation only (n = 2,063), or neither (n = 2,158). Multivariable models were used to assess chemotherapy-associated SMN risk, including dose-response relationships.Of 1,498 SMNs among 1,344 survivors, 229 occurred among 206 survivors treated with chemotherapy only. Thirty-year SMN cumulative incidence was 3.9%, 9.0%, 10.8%, and 3.4% for the chemotherapy-only, chemotherapy plus radiation, radiation-only, or neither-treatment groups, respectively. Chemotherapy-only survivors had a 2.8-fold increased SMN risk compared with the general population (95% CI, 2.5 to 3.2), with SIRs increased for subsequent leukemia/lymphoma (1.9; 95% CI, 1.3 to 2.7), breast cancer (4.6; 95% CI, 3.5 to 6.0), soft-tissue sarcoma (3.4; 95% CI, 1.9 to 5.7), thyroid cancer (3.8; 95% CI, 2.7 to 5.1), and melanoma (2.3; 95% CI, 1.5 to 3.5). SMN rate was associated with > 750 mg/m2 platinum (relative rate [RR] 2.7; 95% CI, 1.1 to 6.5), and a dose response was observed between alkylating agents and SMN rate (RR, 1.2/5,000 mg/m2; 95% CI, 1.1 to 1.3). A linear dose response was also demonstrated between anthracyclines and breast cancer rate (RR, 1.3/100 mg/m2; 95% CI, 1.2 to 1.6).Childhood cancer survivors treated with chemotherapy only, particularly higher cumulative doses of platinum and alkylating agents, face increased SMN risk. Linear dose responses were seen between alkylating agents and SMN rates and between anthracyclines and breast cancer rates. Limiting cumulative doses and consideration of alternate chemotherapies may reduce SMN risk.
Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience
Authors: Francesco Autore, Idanna Innocenti, Francesca Morelli, Federica Sora, Andrea Corbingi, Denise Soldati, Luana Fianchi, Marianna Criscuolo, Livio Pagano, Andrea Bacigalupo, Simona Sica, Luca Laurenti
Journal: Blood (2018)
Abstract 274: Mitochondrial Translation Machinery Defects Causes Cardiomyopathy and i <i>n vivo</i> Functional Screening of Therapeutic Targets
Authors: Feng Gao, Tian Liang, Feng Zhang, Ning Liu, Xuyang Fu, Xiaoxuan Dong, Da-zhi Wang, Jinghai Chen
Journal: Circulation Research (2019)

More than 95% of ATP consumed in the heart is derived from oxidative phosphorylation (OxPhos) in the mitochondria. Besides over a thousand proteins encoded by nuclear DNA, mitochondrial gene expression machinery generates 13 proteins for the OxPhos system that employs mitochondrial ribosomal proteins for translation. Mitochondrial ribosome protein S5 (MRPS5) encoded by MRPs gene family, is located at the mammalian mitochondrial ribosome 28S subunit and its importance has not been explored in the heart. Western blotting showed that MRPS5 expression was decreased in TAC-induced hypertrophic mouse hearts ( in vivo ), and in phenylephrine or isoproterenol-stimulated cardiomyocytes ( in vitro ). In the failing hearts of patients, Mrps5-mediated mt-CO1 was markedly decreased as well. To determine the functional role of MRPS5 in the heart, we generated an inducible cardiac-specific knockout mouse and showed that Mrps5-deficient mice developed time-dependent cardiac hypertrophy, fibrosis and heart failure. Mitochondria in the Mrps5-deficient adult cardiomyocytes exhibited membrane swelling and cristae collapsed together with decreased oxygen consumption and ATP production. Mitochondrial calcium homeostasis was also disrupted. Combined analysis of transcriptomics and metabolomics spatiotemporally identified 20 potential target genes associated with Mrps5 deficiency-mediated cardiac pathological processes. Through in vivo functional screening via adeno-associated virus (AAV) mediated gene delivery, we further narrowed down and confirmed that Kruppel-like factor 15 (Klf15) remarkably rescued cardiac phenotype in the Mrps5-deficient mice with maintained mitochondrial homeostasis, suppressed cardiac hypertrophy and fibrosis, as well as preserved cardiac function. Further RNA-sequencing and biochemical analysis mechanistically revealed that genes involved in glycolysis/ gluconeogenesis, PPAR signaling pathway and biosynthesis of amino acids, markedly altered when exploited AAV-Klf15 gene therapy in Mrps5-deficient mice heart. Our results demonstrates Mrps5 is essential for mitochondrial homeostasis and cardiac function and uncovers Klf15 as a potential therapeutic target for treating cardiac mitochondrial diseases.
Gender Is A Major Determinant of Cytidine Analogue Metabolism and May Contribute to Differences in Treatment Outcomes
Authors: Reda Z Mahfouz, Ania Jankowska, Quteba Ebrahem, Zhenbo Hu, Kenneth K. Chan, Donald Lavelle, Joseph DeSimone, Mikkael A. Sekeres, Ramon V. Tiu, Jaroslaw P. Maciejewski, Yogen Saunthararajah
Journal: Blood (2011)
Abstract 296: B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Exerts Protective Effects Against Myocardial ischemia-Reperfusion Injury in Mice
Authors: Teja Devarakonda, Adolfo G Mauro, Geronimo Guzman, Chad Cain, Anindita Das, Praveen Praveen, M A Hossain, Fadi N Salloum
Journal: Circulation Research (2019)

Background: B7-33 is a peptide derived from the B-chain of human relaxin, and is shown to elicit biased signaling at relaxin receptor 1 (RXFP1) in human cell lines. The influence of B7-33 on myocardial ischemia-reperfusion (IR) injury and associated cardiac adverse remodeling is unknown. Methods and Results: Primary cardiomyocytes and cardiac fibroblasts were isolated from adult CD1 mice and subjected to simulated ischemia-reoxygenation (SIRO). Myocytes were placed in 1% O 2 chamber for 40 min, followed by 1 h of reoxygenation with control (myocyte media) or B7-33 (10, 50 or 100 nM)-infused media. Trypan blue staining showed a significant decrease in cell death with B7-33 concentrations of 50 nM and 100 nM ( Fig. A ).Treating myocytes with B7-33 for 15 min exhibited a dose-dependent increase in Erk1/2 phosphorylation, which reached statistical significance at 100 nM ( Fig. B ). Fibroblasts subjected to 4 h of hypoxia and 15 h of reoxygenation had increased viability (MTT assay) with B7-33 at all concentrations ( Fig. C ). In vivo , CD1 mice were subjected to IR injury via coronary artery ligation for 30 min, followed by 24 h of reperfusion. Vehicle (saline) or B7-33 (10 μg/kg) was injected i.p. at the onset of reperfusion. After 24 h, B7-33-treated mice demonstrated decreased infarct size (TTC stain) ( Fig. D ) and preserved fractional shortening (M-mode echo, Fig. E ) compared to vehicle-treated mice. Conclusion: Reperfusion therapy with B7-33 reduces infarct size post-MI, preserves cardiac function and protects cardiomyocytes and fibroblasts against SIRO. We propose that B7-33 might be effective against acute MI and a possible alternative to recombinant relaxin for clinical utility.
Soluble LR11, a Novel Acute Leukemia Marker, Drastically Induces WT1 mRNA Expression Together with Synergic Activation of Gatas, and the Migration Activity
Authors: Naomi Shimizu, Chiaki Nakaseko, Masahiro Takeuchi, Chikako Ohwada, Shokichi Tsukamoto, Takeharu Kawaguchi, Shio Sakai, Atsuko Yamazaki, Keigo Nishii, Meiji Jiang, Koutaro Yokote, Hideaki Bujo
Journal: Blood (2012)
Romiplostim Treatment Pattern of Adult Chronic Immune Thrombocytopenia in Routine Clinical Care in Three Nordic Countries
Authors: Mette Nørgaard, Nickolaj Risbo Kristensen, Henrik Frederiksen, Shahram Bahmanyar, Waleed Ghanima, Naufil Alam, Anne Gulbech Ording, Henrik Toft Sørensen, Christian Fynbo Christiansen
Journal: Blood (2018)
Increased TGF-β1 expression Cooperates with the Gata1low Mutation in Determining the Gata1low Phenotype in CD1 Mice
Authors: Fabrizio Martelli, Fiorella Ciaffoni, Francesca Masiello, Maria Zingariello, Laura Sancillo, Rosa Alba Rana, Anna Rita F Migliaccio
Journal: Blood (2012)
Patient beliefs and behaviors concerning clinical trials for blood cancers: Outcomes from live-online education.
Authors: Anne Roc, Wendy Turell, Karen Demairo
Journal: Journal of Clinical Oncology (2019)

226 Background: Finding a clinical trial can be overwhelming for patients and caregivers, generating more questions than answers. The Leukemia &amp; Lymphoma Society (LLS) and PlatformQ Health produced a live-online education activity for patients and caregivers to elevate knowledge of clinical trials and competency discussing the topic with their healthcare providers (HCPs). Methods: A 1-hour web-based education launched on April 18, 2018 and made available on-demand for 18 months on www.cancercoachlive.com and www.LLS.org . Topics included the role and benefits of clinical trials for blood cancers, when it is a viable option, and LLS resources. The program featured a MD, LLS clinical trial navigator, patient and caregiver as speakers, and patient-friendly graphics, videos, slides, interactive polling, and live Q&amp;A. Knowledge questions were administered at 3 time points (pre-, immediate post-, 2 mos. post). Responses from these questions, live polls and Q&amp;A were analyzed to determine engagement, lessons learned, and continuing gaps. McNemar test compared matched pair responses (pre/post &amp; pre/2 mos.). Effect size was computed using Cohen’s d. Results: As of May 2019, 1,040 learners participated in the education. At 2 mos. follow-up, 63% reported feeling more in control of their health care decisions, 47% stated they were more willing to participate in a clinical trial, 42% reported the education had a positive impact on communication with their HCPs about clinical trials, and 31% stated their health-related behavior had improved (n = 107, 103, 111, 103). 65 qualitative written entries were shared by learners as examples of feeling more “in control” of their health care decisions. Data from 4 knowledge questions all showed improvements over baseline at both posttest points, with an average pre to post effect size of d = 0.349. Conclusions: Education on clinical trials for patients and caregivers affected by blood cancers, including breaking down barriers of misinformation and fear, can lead to changes in understanding of the benefits and trustworthiness of clinical trials. Interactive live-online education can be a strong tool in reaching patients and caregivers who could benefit from clinical trials.
Single Institution Experience of Gastrointestinal Involvement of Diffuse Large B- Cell Lymphoma: Presentation, Outcomes and Patterns of Treatment Failure
Authors: Puja C. Arora, Victor M. Orellana-Noia, Abeer Alfaraj, Wenzinger Christopher, Sandra Monson, Gina Petroni, Craig A. Portell, Michael E. Williams
Journal: Blood (2018)
Rituximab Exhibits a Long Half-Life Based on a Population Pharmacokinetic Analysis in Non-Hodgkin’s Lymphoma (NHL) Patients.
Authors: Jing Li, Micha Levi, Jean-Eric Charoin, Nicolas Frey, Thian Kheoh, Song Ren, Michael Woo, Amita Joshi, Nancy Valente, Nelson ‘Shasha’ Jumbe
Journal: Blood (2007)
A Phase I-II Study To Determine the Safety, Pharmacokinetics and Potential Efficacy of the Kinesin Spindle Protein (KSP) Inhibitor SB-743921 on Days 1 and 15 of a 28 Day Schedule in Patients with Non-Hodgkin’s or Hodgkin’s Lymphoma.
Authors: Owen A. O’Connor, A. Goy, R.Z. Orlowski, J. Hainsworth, J.P. Leonard, B. Afanasyev, D. Osmanov, L.M. Reyno, M.M. Chen, R.D. Escandon
Journal: Blood (2007)
MRD Status Did Not Correspond to the Relapse Incidence within One Year of Follow-up By Non-Intensive but Non-Interruptive Approach: The First Interim Results of the Russian Prospective Multicenter RALL-2016 Trial for Ph-Negative Adult ALL
Authors: Olga A. Gavrilina, Elena N. Parovichnikova, Vera V. Troitskaya, Galina A. Baskhaeva, Andrey N. Sokolov, Ksenija I. Zarubina, Elena O. Gribanova, Irina V. Galtseva, Tatiana N. Obukhova, Kamil D Kaplanov, Olga Samoilova, Sergey N. Bondarenko, Elena Borisenkova, Valery Lapin, Pervin Zeinalova, Elena E. Zinina, Ekaterina N. Zotina, Tatiana Konstantinova, Mikhail Yu. Drokov, Sergei M. Kulikov, Valery G. Savchenko
Journal: Blood (2018)
Axl-RTK Inhibition Modulates T Cell Functions and Synergizes with Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies
Authors: Reona Sakemura, Nan Yang, Michelle J. Cox, Sutapa Sinha, Mehrdad Hefazi, Michael J. Hansen, Kendall J. Schick, Cynthia L. Forsman, Justin C. Boysen, Renee C Tschumper, Elizabeth Juarez Diaz, Lars Mouritsen, Jason M Foulks, Steven L. Warner, Sameer A. Parikh, Wei Ding, Neil E. Kay, Saad S. Kenderian
Journal: Blood (2018)